

# Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin and 5-fluorouracil against epirubicin, cisplatin and 5-fluorouracil

<b>Submission date</b> 03/07/2006	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 28/07/2006	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
<b>Last Edited</b> 25/09/2009	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Sanambar Sadighi

**Contact details**  
Cancer Institute  
Emam Hospital  
Tehran  
Iran  
-  
ssadighi@doctor.com

## Additional identifiers

## Study information

Scientific Title

Study objectives

Quality of life does not differ in advanced gastric cancer patients after receiving either docetaxel, cisplatin and 5-fluorouracil (5-FU) (TCF regimen) versus epirubicin, cisplatin and 5-FU (ECF-regimen).

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Ethics committee of the Tehran University of Medical Sciences November 2001

**Study design**

Randomised controlled trial

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Gastric cancer

**Interventions**

Three to six cycles of either ECF (epirubicin 60 mg/m<sup>2</sup>, cisplatin 60 mg/m<sup>2</sup> and 5-FU 750 mg/m<sup>2</sup>/day as a five-day continuous infusion) or TCF regimen (docetaxel 60 mg/m<sup>2</sup>, cisplatin 60 mg/m<sup>2</sup> and 5FU in the same dose and schedule of ECF) every three weeks.

**Intervention Type**

Other

**Phase**

Not Specified

**Primary outcome(s)**

Response rate

**Key secondary outcome(s))**

Quality of life and survival

**Completion date**

01/01/2005

**Eligibility****Key inclusion criteria**

Patients with histologically confirmed advanced gastric cancer

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Sex**

All

**Key exclusion criteria**

Patients with local or local- regional gastric cancer

**Date of first enrolment**

01/01/2002

**Date of final enrolment**

01/01/2005

**Locations****Countries of recruitment**

Iran

**Study participating centre**

Cancer Institute

Tehran

Iran

-

**Sponsor information****Organisation**

Tehran University of Medical Sciences (Iran)

**ROR**

<https://ror.org/01c4pz451>

**Funder(s)****Funder type**

University/education

## Funder Name

Tehran University of Medical Sciences (Iran)

# Results and Publications

## Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	05/12/2006		Yes	No